BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Turpie AGG, Purdham D, Ciaccia A. Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment. Ther Adv Cardiovasc Dis. 2017;11:243-256. [PMID: 28651452 DOI: 10.1177/1753944717714921] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Ameku K, Higa M. Rivaroxaban Treatment for Warfarin-Refractory Thrombosis in a Patient with Hereditary Protein S Deficiency. Case Rep Hematol 2018;2018:5217301. [PMID: 29607227 DOI: 10.1155/2018/5217301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Meihandoest T, Studt JD, Mendez A, Alberio L, Fontana P, Wuillemin WA, Schmidt A, Graf L, Gerber B, Maeder GM, Bovet C, Sauter TC, Nagler M. Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements. Front Cardiovasc Med 2021;8:717939. [PMID: 34568459 DOI: 10.3389/fcvm.2021.717939] [Reference Citation Analysis]
3 Dalgaard F, Xu H, Matsouaka RA, Russo AM, Curtis AB, Rasmussen PV, Ruwald MH, Fonarow GC, Lowenstern A, Hansen ML, Pallisgaard JL, Alexander KP, Alexander JH, Lopes RD, Granger CB, Lewis WR, Piccini JP, Al-Khatib SM. Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines-Atrial Fibrillation. J Am Heart Assoc 2020;9:e017024. [PMID: 33241750 DOI: 10.1161/JAHA.120.017024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
4 Yhim HY. Challenging issues in the management of cancer-associated venous thromboembolism. Blood Res 2022;57:44-8. [PMID: 35483925 DOI: 10.5045/br.2022.2022025] [Reference Citation Analysis]
5 Kohsaka S, Katada J, Saito K, Jenkins A, Li B, Mardekian J, Terayama Y. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data. Open Heart 2020;7:e001232. [PMID: 32341789 DOI: 10.1136/openhrt-2019-001232] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
6 AlShoaibi N, Al Harbi M, Modaimegh H, Al Qubbany A, Al Saif S, Connolly DL, Kharabsheh S, Fathy M, Hegazy Y, Tarcha N, Al Fagih A. Use of NOACS in high-risk patients with atrial fibrillation in Saudi Arabia: Perspectives on improving patient care. Expert Rev Cardiovasc Ther 2021;19:221-36. [PMID: 33475462 DOI: 10.1080/14779072.2021.1878878] [Reference Citation Analysis]
7 Moudallel S, Cornu P, Dupont A, Steurbaut S. Determinants for under- and overdosing of direct oral anticoagulants and physicians' implementation of clinical pharmacists' recommendations. Br J Clin Pharmacol 2021. [PMID: 34331720 DOI: 10.1111/bcp.15017] [Reference Citation Analysis]
8 Miglinas M, Cesniene U, Janusaite MM, Vinikovas A. Cerebrovascular Disease and Cognition in Chronic Kidney Disease Patients. Front Cardiovasc Med 2020;7:96. [PMID: 32582768 DOI: 10.3389/fcvm.2020.00096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
9 Rivera-Lebron B, Bauersachs R. Direct oral anticoagulants for the treatment of pulmonary embolism in patients with renal impairment. Thromb Res 2021;204:101-7. [PMID: 34167039 DOI: 10.1016/j.thromres.2021.06.011] [Reference Citation Analysis]
10 Santos J, António N, Rocha M, Fortuna A. Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review. Br J Clin Pharmacol 2020;86:533-47. [PMID: 31631392 DOI: 10.1111/bcp.14127] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
11 Chong DT, Andreotti F, Verhamme P, Dalal J, Uaprasert N, Wang CC, On YK, Li YH, Jiang J, Hasegawa K, Almuti K, Bai R, Lo ST, Krittayaphong R, Lee LH, Quek DK, Johar S, Seow SC, Hammett CJ, Tan JW. Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation: Consensus Recommendations by the Asian Pacific Society of Cardiology on Strategies for Thrombotic and Bleeding Risk Management. Eur Cardiol 2021;16:e23. [PMID: 34135993 DOI: 10.15420/ecr.2020.43] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Cicora F, Petroni J, Roberti J. Prophylaxis of Pulmonary Embolism in Kidney Transplant Recipients. Curr Urol Rep 2018;19. [DOI: 10.1007/s11934-018-0759-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Bukhari MA, Al-Theaby A, Tawhari M, Al-Shaggag A, Pyrke R, Gangji A, Treleaven D, Ribic C. Efficacy and safety of non-vitamin K antagonist oral anticoagulants post-kidney transplantation. World J Transplant 2019; 9(6): 134-144 [PMID: 31750090 DOI: 10.5500/wjt.v9.i6.134] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Kruger PC, Eikelboom JW, Douketis JD, Hankey GJ. Deep vein thrombosis: update on diagnosis and management. Medical Journal of Australia 2019;210:516-24. [DOI: 10.5694/mja2.50201] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
15 Sexton DJ, de Freitas DG, Little MA, McHugh T, Magee C, Conlon PJ, O'Seaghdha CM. Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome. Kidney Int Rep 2018;3:784-93. [PMID: 29989039 DOI: 10.1016/j.ekir.2018.02.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
16 Khan Y, Zaidi SO, Razak BS, Zaki M, Malik BH. Use of New Oral Anticoagulants / Direct Oral Anticoagulants in Malignant Patients. Cureus 2020;12:e7007. [PMID: 32206471 DOI: 10.7759/cureus.7007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]